OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ACRE56

Accretion Nutraveda Ltd

PharmaceuticalsVerified

Capital Structure and Liquidity Accretion Nutraveda has a debt-to-equity ratio of 0.72, indicating a moderate level of leverage. The company's liquidity position is assessed as medium, with a current ratio of 2.24, suggesting it can cover its short-term obligations but with limited excess capacity. However, the company has negative net cash after subtracting total debt, which raises concerns about its short-term liquidity. ### Profitability and Returns The company's return on equity (ROE) is 48.85%, and its return on assets (ROA) is 24.05%, both of which are strong indicators of efficient use of equity and assets. These returns are well above the typical thresholds for the pharmaceutical industry, suggesting that Accretion Nutraveda is generating robust returns relative to its capital base. ### Segments and Geographic Exposure Accretion Nutraveda operates in a single business segment focused on Ayurvedic and Nutraceutical products. The company's revenue is primarily concentrated in India, with no disclosed international operations. This geographic concentration may expose the company to regulatory and economic risks specific to the Indian market. ### Growth Trajectory The company's revenue for the latest period is INR 160.02 million. While historical revenue growth data is not provided, the company's strong ROE and ROA suggest it is effectively managing its operations and could be positioned for growth. However, the negative operating cash flow of INR -22.13 million indicates potential challenges in converting operations into cash, which could impact future growth. ### Risk Factors The company faces a medium liquidity risk due to its current ratio and negative net cash position. The dilution risk is assessed as low, with no significant dilution potential identified. The company's capital expenditure of INR -8.72 million suggests it is investing in its operations, but the negative operating cash flow could limit its ability to sustain such investments without external financing. ### Recent Events No specific recent events such as filings or transcripts are provided in the input data. The company's financial snapshot indicates a strong balance sheet in terms of equity and assets, but the negative operating cash flow and net cash position suggest potential liquidity challenges that may require monitoring.

30-day price · ACRE+67.00 (+32.7%)
Low$193.55High$300.00Close$272.00As of17 May, 00:00 UTC
Profile
CompanyAccretion Nutraveda Ltd
TickerACRE.BO
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Accretion Nutraveda Limited is an India-based healthcare company engaged in the manufacturing and sale of pharmaceutical products, including Ayurvedic and Nutraceutical products in various dosage forms such as tablets, capsules, oral liquids, and oils.

Classification. Accretion Nutraveda is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

### Capital Structure and Liquidity Accretion Nutraveda has a debt-to-equity ratio of 0.72, indicating a moderate level of leverage. The company's liquidity position is assessed as medium, with a current ratio of 2.24, suggesting it can cover its short-term obligations but with limited excess capacity. However, the company has negative net cash after subtracting total debt, which raises concerns about its short-term liquidity. ### Profitability and Returns The company's return on equity (ROE) is 48.85%, and its return on assets (ROA) is 24.05%, both of which are strong indicators of efficient use of equity and assets. These returns are well above the typical thresholds for the pharmaceutical industry, suggesting that Accretion Nutraveda is generating robust returns relative to its capital base. ### Segments and Geographic Exposure Accretion Nutraveda operates in a single business segment focused on Ayurvedic and Nutraceutical products. The company's revenue is primarily concentrated in India, with no disclosed international operations. This geographic concentration may expose the company to regulatory and economic risks specific to the Indian market. ### Growth Trajectory The company's revenue for the latest period is INR 160.02 million. While historical revenue growth data is not provided, the company's strong ROE and ROA suggest it is effectively managing its operations and could be positioned for growth. However, the negative operating cash flow of INR -22.13 million indicates potential challenges in converting operations into cash, which could impact future growth. ### Risk Factors The company faces a medium liquidity risk due to its current ratio and negative net cash position. The dilution risk is assessed as low, with no significant dilution potential identified. The company's capital expenditure of INR -8.72 million suggests it is investing in its operations, but the negative operating cash flow could limit its ability to sustain such investments without external financing. ### Recent Events No specific recent events such as filings or transcripts are provided in the input data. The company's financial snapshot indicates a strong balance sheet in terms of equity and assets, but the negative operating cash flow and net cash position suggest potential liquidity challenges that may require monitoring.
Key takeaways
  • Accretion Nutraveda has a strong return on equity (48.85%) and return on assets (24.05%), indicating efficient use of capital.
  • The company's debt-to-equity ratio of 0.72 suggests moderate leverage, but its liquidity position is assessed as medium.
  • Revenue is concentrated in India, with no disclosed international operations, which may increase regulatory and economic risks.
  • The company has negative operating cash flow and net cash after subtracting total debt, which could impact its ability to sustain operations and investments.
  • The dilution risk is low, and the company's capital expenditure suggests ongoing investment in operations.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$160.0M
Gross profit$54.3M
Operating income$34.8M
Net income$26.1M
R&D
SG&A
D&A
SBC
Operating cash flow-$22.1M
CapEx-$8.7M
Free cash flow$19.8M
Total assets$108.6M
Total liabilities$55.1M
Total equity$53.5M
Cash & equivalents
Long-term debt$38.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$53.5M
Net cash-$38.6M
Current ratio2.2
Debt/Equity0.7
ROA24.1%
ROE48.9%
Cash conversion-85.0%
CapEx/Revenue-5.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
MetricACREActivity
Op margin21.8%-2.9% medp25 -218.9% · p75 9.6%top quartile
Net margin16.3%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin34.0%47.8% medp25 27.6% · p75 68.9%below median
CapEx / revenue-5.5%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity72.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 19:04 UTC#ea45c70e
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 19:06 UTCJob: 64cedda7